Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2023 2023-08-10
DATE OF BOARD MEETING 2023-08-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023 2023-08-03
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE III CLINICAL TRIAL OF KN026 IN COMBINATION WITH HB1801 FOR THE FIRST-LINE TREATMENT OF HER2-POSITIVE METASTATIC BC 2023-07-28
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023 2023-07-06
RESIGNATION OF A NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE 2023-06-30
AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION 2023-06-12
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2023 2023-06-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2023 2023-06-06
VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON KN026 IN COMBINATION WITH KN046 FOR PRESENTATION AT 2023 ASCO ANNUAL MEETING 2023-06-06

6 7 8 9 10 11 12